These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 35213007)
1. Introduction and History of the Chemistry of Nucleic Acids Therapeutics. Gait MJ; Agrawal S Methods Mol Biol; 2022; 2434():3-31. PubMed ID: 35213007 [TBL] [Abstract][Full Text] [Related]
2. Challenges and Opportunities for Nucleic Acid Therapeutics. Corey DR; Damha MJ; Manoharan M Nucleic Acid Ther; 2022 Feb; 32(1):8-13. PubMed ID: 34931905 [TBL] [Abstract][Full Text] [Related]
3. Re-Engineering RNA Molecules into Therapeutic Agents. Egli M; Manoharan M Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917 [TBL] [Abstract][Full Text] [Related]
4. Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. Xu L; Anchordoquy T J Pharm Sci; 2011 Jan; 100(1):38-52. PubMed ID: 20575003 [TBL] [Abstract][Full Text] [Related]
5. Stereocontrolled Oligonucleotides for Nucleic Acid Therapeutics: A Perspective. Meena ; Lemaitre MM Nucleic Acid Ther; 2021 Feb; 31(1):1-6. PubMed ID: 33305971 [No Abstract] [Full Text] [Related]
6. Nucleic acid therapeutics for hematologic malignancies--theoretical considerations. Opalinska JB; Kalota A; Chattopadhyaya J; Damha M; Gewirtz AM Ann N Y Acad Sci; 2006 Oct; 1082():124-36. PubMed ID: 17145934 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic Oligonucleotides: State of the Art. Smith CIE; Zain R Annu Rev Pharmacol Toxicol; 2019 Jan; 59():605-630. PubMed ID: 30285540 [TBL] [Abstract][Full Text] [Related]
8. [Recent progress and prospect in oligonucleotide therapeutics]. Yoshioka K; Kuwahara H; Nishina K; Nagata T; Yokota T Nihon Rinsho; 2015 Jun; 73(6):1057-65. PubMed ID: 26065142 [TBL] [Abstract][Full Text] [Related]
9. Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA. Grünweller A; Wyszko E; Bieber B; Jahnel R; Erdmann VA; Kurreck J Nucleic Acids Res; 2003 Jun; 31(12):3185-93. PubMed ID: 12799446 [TBL] [Abstract][Full Text] [Related]
10. Sugar boost: when ribose modifications improve oligonucleotide performance. Faria M; Ulrich H Curr Opin Mol Ther; 2008 Apr; 10(2):168-75. PubMed ID: 18386229 [TBL] [Abstract][Full Text] [Related]
11. Targeting nucleic acid-based therapeutics to tumors: Challenges and strategies for polyplexes. Vetter VC; Wagner E J Control Release; 2022 Jun; 346():110-135. PubMed ID: 35436520 [TBL] [Abstract][Full Text] [Related]
12. Advancing Nucleic Acid Therapeutics by Setting Uniform Standards for Experimental Controls. Aartsma-Rus A; Krieg AM Nucleic Acid Ther; 2019 Jun; 29(3):115. PubMed ID: 30964415 [No Abstract] [Full Text] [Related]
15. Prospects for nucleic acid-based therapeutics against hepatitis C virus. Lee CH; Kim JH; Lee SW World J Gastroenterol; 2013 Dec; 19(47):8949-62. PubMed ID: 24379620 [TBL] [Abstract][Full Text] [Related]
16. Post-transcriptional gene silencing by nucleic acid gapmers: a promising therapeutic modality for cancer. Priyadharsini JV; Arumugam P Epigenomics; 2023 Jan; 15(2):53-56. PubMed ID: 36802730 [No Abstract] [Full Text] [Related]
18. The current landscape of nucleic acid therapeutics. Kulkarni JA; Witzigmann D; Thomson SB; Chen S; Leavitt BR; Cullis PR; van der Meel R Nat Nanotechnol; 2021 Jun; 16(6):630-643. PubMed ID: 34059811 [TBL] [Abstract][Full Text] [Related]
19. Progress on RNA-based therapeutics for genetic diseases. Luo T; Huo C; Zhou T; Xie S Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Aug; 52(4):406-416. PubMed ID: 37643975 [TBL] [Abstract][Full Text] [Related]
20. Nucleic acids-based therapeutics in the battle against pathogenic viruses. Haasnoot J; Berkhout B Handb Exp Pharmacol; 2009; 189(189):243-63. PubMed ID: 19048203 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]